CORDIS
EU research results

CORDIS

English EN

Creutzfeldt-Jakob disease: epidemiology, risk factors, diagnostic tests and genetics

Project information

Grant agreement ID: QLK2-CT-2001-02248

  • Start date

    1 October 2001

  • End date

    30 September 2005

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 997 506

  • EU contribution

    € 997 506

Coordinated by:

STATENS SERUM INSTITUT

Denmark

Objective

There is compelling evidence that the same agent is responsible for variant CJD (vCJD) and bovine spongiform encephalopathy. Cases of vCJD have been identified in the UK, France and the Republic of Ireland. It is not possible to predict the numbers of cases that may occur in European countries. It is essential to monitor this disease and to identify relevant risk factors for vCJD. In order to achieve this, it is necessary to identify all forms of CJD, including atypical phenotypes of sporadic CJD (sCJD). Prion protein (PrP) genotype is an important determinant of disease susceptibility and phenotype. Detailed population studies of PrP genotype are necessary in order to address issues of age and gender distributions of CJD within a given region and issues of differing incidence between regions. This proposal addresses these objectives through the co-ordination and harmonization.

Coordinator

STATENS SERUM INSTITUT

Address

5,Artillerivej 5
2300 Koepenhagen

Denmark

Participants (11)

BARJIIAL MEDICAL CENTRE

Israel

BEAUMONT HOSPITAL

Ireland

ERASMUS UNIVERSITEIT ROTTERDAM

Netherlands

NATIONAL PUBLIC HEALTH INSTITUTE

Finland

NORWEGIAN INSTITUTE OF PUBLIC HEALTH

Norway

SCIENTIFIC INSTITUTE OF PUBLIC HEALTH

Belgium

SMITTSKYDDSINSTITUTET

Sweden

UNIVERSIDADE DE LISBOA

Portugal

UNIVERSITAIRE INSTELLING ANTWERPEN - UNIVERSITEIT ANTWERPEN

Belgium

UNIVERSITY OF HELSINKI

Finland

UNIVERSITY OF ICELAND

Iceland

Project information

Grant agreement ID: QLK2-CT-2001-02248

  • Start date

    1 October 2001

  • End date

    30 September 2005

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 997 506

  • EU contribution

    € 997 506

Coordinated by:

STATENS SERUM INSTITUT

Denmark